402 related articles for article (PubMed ID: 15270197)
1. Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.
Chen F; David D; Ferrari A; Götz J
Curr Drug Targets; 2004 Aug; 5(6):503-15. PubMed ID: 15270197
[TBL] [Abstract][Full Text] [Related]
2. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
3. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology.
Song L; Lu SX; Ouyang X; Melchor J; Lee J; Terracina G; Wang X; Hyde L; Hess JF; Parker EM; Zhang L
Mol Neurodegener; 2015 Mar; 10():14. PubMed ID: 25881209
[TBL] [Abstract][Full Text] [Related]
4. Tau Abnormalities and the Potential Therapy in Alzheimer's Disease.
Almansoub HAMM; Tang H; Wu Y; Wang DQ; Mahaman YAR; Wei N; Almansob YAM; He W; Liu D
J Alzheimers Dis; 2019; 67(1):13-33. PubMed ID: 30507581
[TBL] [Abstract][Full Text] [Related]
5. Tau and transgenic animal models.
Götz J
Brain Res Brain Res Rev; 2001 Jul; 35(3):266-86. PubMed ID: 11423157
[TBL] [Abstract][Full Text] [Related]
6. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
7. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
[TBL] [Abstract][Full Text] [Related]
8. The role of tau phosphorylation and cleavage in neuronal cell death.
Chun W; Johnson GV
Front Biosci; 2007 Jan; 12():733-56. PubMed ID: 17127334
[TBL] [Abstract][Full Text] [Related]
9. Transgenic Drosophila models of Alzheimer's disease and tauopathies.
Iijima-Ando K; Iijima K
Brain Struct Funct; 2010 Mar; 214(2-3):245-62. PubMed ID: 19967412
[TBL] [Abstract][Full Text] [Related]
10. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.
Sorrentino G; Bonavita V
Neurol Sci; 2007 Apr; 28(2):63-71. PubMed ID: 17464468
[TBL] [Abstract][Full Text] [Related]
11. Post-translational modifications of tau protein in Alzheimer's disease.
Gong CX; Liu F; Grundke-Iqbal I; Iqbal K
J Neural Transm (Vienna); 2005 Jun; 112(6):813-38. PubMed ID: 15517432
[TBL] [Abstract][Full Text] [Related]
12. P301 L, an FTDP-17 Mutant, Exhibits Enhanced Glycation in vitro.
Sonawane SK; Chinnathambi S
J Alzheimers Dis; 2020; 75(1):61-71. PubMed ID: 32250308
[TBL] [Abstract][Full Text] [Related]
13. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.
Liu K; Liu Y; Li L; Qin P; Iqbal J; Deng Y; Qing H
Biochim Biophys Acta; 2016 Feb; 1862(2):192-201. PubMed ID: 26655600
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
[TBL] [Abstract][Full Text] [Related]
15. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
Brandt R; Hundelt M; Shahani N
Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
[TBL] [Abstract][Full Text] [Related]
16. Degradation or aggregation: the ramifications of post-translational modifications on tau.
Park S; Lee JH; Jeon JH; Lee MJ
BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
[TBL] [Abstract][Full Text] [Related]
17. Modulation of tau pathology in tau transgenic models.
Brion JP; Ando K; Heraud C; Leroy K
Biochem Soc Trans; 2010 Aug; 38(4):996-1000. PubMed ID: 20658992
[TBL] [Abstract][Full Text] [Related]
18. Post-translational modifications of tau protein: implications for Alzheimer's disease.
Martin L; Latypova X; Terro F
Neurochem Int; 2011 Mar; 58(4):458-71. PubMed ID: 21215781
[TBL] [Abstract][Full Text] [Related]
19. A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease.
García-Escudero V; Ruiz-Gabarre D; Gargini R; Pérez M; García E; Cuadros R; Hernández IH; Cabrera JR; García-Escudero R; Lucas JJ; Hernández F; Ávila J
Acta Neuropathol; 2021 Jul; 142(1):159-177. PubMed ID: 33934221
[TBL] [Abstract][Full Text] [Related]
20. A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations
Bardai FH; Wang L; Mutreja Y; Yenjerla M; Gamblin TC; Feany MB
J Neurosci; 2018 Jan; 38(1):108-119. PubMed ID: 29138281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
